Taysha Gene Therapies TSHA

$ 1.86 0.27%

Quarterly report 2024-Q3
added 11-13-2024

Taysha Gene Therapies Balance Sheet 2011-2024 | TSHA

Annual Balance Sheet Taysha Gene Therapies

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-102 M	-48.7 M	-112 M	-251 M	-	-	-	-	-	-	-	-	-
Long Term Debt	40.5 M	38 M	37.2 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1.29 M	1.2 M	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	450 K	-	-	-	-	-	-	-	-	-
Total Current Liabilities	36.8 M	62.8 M	51.7 M	7.13 M	-	-	-	-	-	-	-	-	-
Total Liabilities	97.8 M	125 M	119 M	7.58 M	150 K	-	-	-	-	-	-	-	-
Deferred Revenue	18.1 M	33.6 M	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-513 M	-401 M	-236 M	-61.1 M	-1.12 M	-	-	-	-	-	-	-	-
Total Assets	173 M	126 M	214 M	259 M	15 K	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	144 M	87.9 M	149 M	251 M	-	-	-	-	-	-	-	-	-
Book Value	74.9 M	949 K	95.4 M	251 M	-135 K	-	-	-	-	-	-	-	-
Total Shareholders Equity	74.9 M	949 K	95.4 M	251 M	-135 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Taysha Gene Therapies

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	43 M	37.8 M	40.5 M	40.5 M	38.5 M	38.4 M	38.2 M	38 M	37.8 M	37.6 M	37.4 M	37.2 M	27.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	91.4 M	91.5 M	99.2 M	97.8 M	245 M	119 M	117 M	125 M	100 M	110 M	115 M	119 M	101 M	55.4 M	20 M	7.58 M	7.58 M	7.58 M	7.58 M	150 K	150 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	11.8 M	13.6 M	14.7 M	18.1 M	18.8 M	20.2 M	28.9 M	33.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-584 M	-558 M	-537 M	-513 M	-561 M	-444 M	-419 M	-401 M	-346 M	-320 M	-286 M	-236 M	-185 M	-134 M	-93.2 M	-61.1 M	-61.1 M	-61.1 M	-61.1 M	-1.12 M	-1.12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	180 M	200 M	153 M	173 M	196 M	81.5 M	102 M	126 M	111 M	142 M	166 M	214 M	241 M	242 M	243 M	259 M	259 M	259 M	259 M	15 K	15 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	158 M	173 M	124 M	144 M	164 M	45.1 M	63.4 M	87.9 M	34.3 M	66.2 M	96.6 M	149 M	189 M	197 M	229 M	251 M	251 M	251 M	251 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	88.8 M	109 M	53.8 M	74.9 M	-49.1 M	-37.1 M	-14.9 M	949 K	11.1 M	32.7 M	50.7 M	95.4 M	140 M	186 M	223 M	251 M	251 M	251 M	251 M	-135 K	-135 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	88.8 M	109 M	53.8 M	74.9 M	-49.1 M	-37.1 M	-14.9 M	949 K	10.7 M	32.5 M	50.7 M	95.4 M	140 M	186 M	223 M	251 M	251 M	251 M	251 M	-135 K	-135 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency